Thelma Young-Bolden
Psychiatric/Mental Health, Adult · Bloomington, INNPI 1316910367
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 206 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations.
Across 206 payments — averaging $27.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$976
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$845
- Alkermes, Inc.$794
- Johnson & Johnson$549
- AbbVie$505
- Axsome Therapeutics, Inc.$407
- plus $2K from 15 others
What the payments were for
- Food & beverage$5,48498%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 30 | $976 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 21 | $845 |
| Alkermes, Inc. | 28 | $794 |
| Johnson & Johnson | 16 | $549 |
| AbbVie | 25 | $505 |
| Axsome Therapeutics, Inc. | 8 | $407 |
| Neurocrine Biosciences, Inc. | 27 | $378 |
| Otsuka America Pharmaceutical, Inc. | 16 | $292 |
| Vanda Pharmaceuticals Inc. | 5 | $250 |
| E.r. Squibb & Sons, L.L.C. | 6 | $173 |
| Lundbeck LLC | 6 | $118 |
| Noven Therapeutics, LLC | 3 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $50 |
| Supernus Pharmaceuticals, Inc. | 3 | $48 |
| Gilead | 2 | $37 |
| Idorsia Pharmaceuticals US Inc | 2 | $36 |
| Indivior Inc. | 1 | $20 |
| UCB, Inc. | 1 | $15 |
| OWP Pharmaceuticals, Inc. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Corium, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$642
- ARISTADA$429
- Austedo XR$240
- Fanapt$126
- INVEGA TRINZA$124
- INVEGA SUSTENNA$124
- AUSTEDO$114
- ARISTADA INITIO$107
How this compares
Too few psychiatric/mental health, adult providers in Indianato place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega TrinzaPaliperidone Palmitate | 20 | $181,494 |
| Invega SustennaPaliperidone Palmitate | 50 | $151,854 |
| Austedo XrDeutetrabenazine | 26 | $134,331 |
| AustedoDeutetrabenazine | 15 | $105,248 |
| IngrezzaValbenazine Tosylate | 13 | $97,686 |
| VraylarCariprazine Hcl | 34 | $48,397 |
| CaplytaLumateperone Tosylate | 20 | $32,714 |
| RexultiBrexpiprazole | 13 | $20,866 |
| TrintellixVortioxetine Hydrobromide | 28 | $18,259 |
| QelbreeViloxazine Hcl | 11 | $9,563 |
| Paliperidone ErPaliperidone | 37 | $8,522 |
| Clozapine | 25 | $6,869 |
| Olanzapine | 147 | $5,135 |
| Divalproex Sodium ErDivalproex Sodium | 67 | $4,980 |
| Buspirone Hcl | 247 | $4,540 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $549 | $333,34770 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $976 | $239,58041 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $378 | $97,68613 claims |
| AbbVieVraylar | $505 | $48,39734 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $845 | $32,71420 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $292 | $20,86613 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $50 | $18,25928 claims |
| Supernus Pharmaceuticals, Inc.Qelbree | $48 | $9,56311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few psychiatric/mental health, adult providers in Indianaon file to place this against a meaningful peer group, so we don't.
Other psychiatric/mental health, adult in Bloomington
- Julia FonteCarmel$21K
- Lyndsay HillIndianapolis$6K
- Deborah BykowskiCarmel$3K
- Noreen NowakIndianapolis$2K
- Cynthia WilsonCarmel$2K
- Mary HessionIndianapolis$1K
- Ashlynn DavisLafayette$1K
- Jane NewkirkIndianapolis$1K
- Leah KnightIndianapolis$1K
- Valerie MarkleyTerre Haute$732
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.